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Abstract
Introduction: Bronchoalveolar lavage (BAL) is useful for diagnosing diffuse lung disease and excluding other conditions. However, 
acute exacerbations (AEs) are recognized as important complications of BAL in patients with idiopathic pulmonary fibrosis (IPF). 
This study aimed to identify risk factors for BAL-induced AEs in patients with IPF.
Material and methods: We retrospectively analyzed the data of 155 patients with suspected IPF who had undergone BAL 
between January 2013 and December 2018. BAL-related AE was defined as the development of AE within 30 days after the 
procedure. We compared clinical features and parameters between patients with AE (AE group) and without AE (non-AE group). 
We also reviewed the relevant reported literature.
Results: Among the 155 patients, 5 (3.2%) developed AE within 30 days after BAL. The average duration from BAL to AE onset 
was 7.8 days (2–16 days). Results from the univariate analysis revealed PaO2 < 75 mm Hg (p = 0.036), neutrophil content in BAL 
≥ 7% (p = 0.0061), %DLCO < 50% (p = 0.019), Gender-Age-Physiology (GAP) stage III (p = 0.034), and BAL recovery rates < 
30% (p < 0.001) as significant risk factors for post-BAL AE. All five patients who developed AE recovered and were discharged.
Conclusions: Disease severity, high neutrophil levels in BAL, and poor BAL recovery rates may be risk factors for BAL-induced AEs.
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Introduction
Bronchoalveolar lavage (BAL) is a standard 
tool for the diagnostic and prognostic evaluation 
of diffuse lung diseases [1–3]. BAL is useful for 
differentiating idiopathic pulmonary fibrosis 
(IPF) from other fibrosing lung diseases, such 
as non-specific interstitial pneumonia (NSIP), 
chronic hypersensitivity pneumonia (CHP), and 
interstitial pneumonia due to collagen and vascu-
litis disease. Ohshimo et al. [4] reported that 8% of 
patients with a usual interstitial pneumonia (UIP) 
pattern on high-resolution computed tomography 
(HRCT) might have BAL findings suggestive of 
such an alternative diagnosis. 
Clinical rationale for the study
The American Thoracic Society (ATS), 
European Respiratory Society (ERS), Japanese 
Respiratory Society (JRS), and Latin American 
Thoracic Society (ALAT) 2011 guidelines ad-
vocated that the most important application of 
BAL when evaluating patients with suspected 
IPF is CHP exclusion; prominent lymphocy-
tosis (> 40%) should suggest CHP [5]. The 
ATS/JRS/ALAT 2020 guidelines on CHP by Ra-
ghu et al. described the importance of BAL in 
diagnosing CHP [6]. Per the ATS/ERS/JRS/ALAT 
2018 guidelines [7], BAL is not recommended 
for patients with a UIP pattern because of the 
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risk of acute exacerbation (AE) of IPF (AE-IPF) 
[8, 9]. Sakamoto et al. [8] reviewed 12 cases of 
BAL-induced AE-IPF and found that functional 
impairment or active inflammation may be risk 
factors for BAL-induced AE. Only patient factors 
were reported; no risk factors were evaluated for 
bronchoscopic procedures.
Therefore, this study aimed to evaluate the 
previously proposed risk factors for IPF-AE after 
BAL and identify other novel risk factors for IPF-
AE after BAL.
Material and methods
Our single-center retrospective study was 
approved by our human ethics committee (proto-
col number 2083). We obtained informed consent 
with an opt-out option. The study was conducted 
in accordance with the ethical principles of the 
1964 Declaration of Helsinki and subsequent 
amendments.
Patients
Between January 2013 and December 2018, 
806 consecutive patients underwent BAL at our 
hospital. Among them, 629 subjects were suspect-
ed of having non-IPF diseases, including an “alter-
native diagnosis” per the 2018 ATS/ERS/JRS/ALAT 
statement [7]; drug-induced lung injury; intersti-
tial lung disease with collagen vascular disease; 
acute respiratory distress syndrome; etc.; there-
fore, they were excluded from our analysis. Twen-
ty-two patients suspected of having AE at the time 
of BAL were excluded. Finally, 155 individuals 
suspected of having stable (non-exacerbation) IPF 
were analyzed (Figure 1). Then, these patients 
underwent their first BAL procedure.
UIP pattern on HRCT
Radiological diagnosis on HRCT (UIP, prob-
able UIP, and indeterminate for UIP) was deter-
mined per the 2018 ATS/ERS/JRS/ALAT guide-
lines [7]. After discussion between two respira-
tory specialists, the HRCT pattern was classified 
as either UIP (n = 68), probable UIP (n = 57), or 
indeterminate for UIP (n = 30) (Table 1). 
IPF confidence
Surgical lung biopsy was performed in eight 
cases. The final diagnoses were expressed using 
the four diagnostic confirmation levels proposed 
by Ryerson et al. [10]: a “confident diagnosis” 
meets ≥ 90% of the guidelines, a “high-confidence 
diagnosis” meets 70–89%, a “low-confidence di-
Figure 1. Study flow chart. We identified 806 consecutive patients who underwent bronchoalveolar lavage (BAL) from April 2013 to December 
2018. Of them, 629 patients were diagnosed with diseases other than suspected IPF; therefore, they were excluded from the analysis. Additional 22 
patients with acute exacerbation were excluded. Therefore, 155 individuals were enrolled in the study. Five patients developed acute exacerbation 
within 30 days after the BAL procedure. BAL — bronchoalveolar lavage; IPF — idiopathic pulmonary fibrosis; AE — acute exacerbation
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agnosis” meets 51–69%, and an “unclassifiable 
diagnosis” meets < 50% (Table 1). 
Gender-age-physiology stage
Gender-Age-Physiology (GAP) stages were 
calculated per the criteria reported by Ley et al. 
[11]: sex (female, 0 points; male, 1 point), age (≤ 
60 years, 0 points; 61–65 years, 1 point; > 65, 
2 points), predicted forced vital capacity (%FVC) (> 
75%, 0 points; 50–75%, 1 point; < 50%, 2 points), 
and predicted diffusing capacity for carbon mon-
oxide (%DLCO) (> 55%, 0 points; 36–55%, 1 point; 
≤ 35%, 2 points; cannot obtain DLCO, 3 points). The 
patients were divided into the following GAP stag-
es based on their total GAP score: I (0–3 points), 
II (4–5 points), and III (6–8 points).
BAL procedures
BAL procedures were performed using a flex-
ible bronchoscope with a 5.9-mm outer diameter 
(BF-1TQ290 or BF-6C260; Olympus Corporation, 
Tokyo, Japan) under intravenous anesthesia. 
Sterile saline (0.9% NaCl) at room temperature 
was instilled through the bronchoscope. Per 
the commonly used methodology in Japan, the 
total instilled volume of saline was 150 mL 
(50 mL × 3 times). As the lavage site, 127 cases 
were in the middle lobe or lingula, and 28 were 
at other sites. The lavage site was determined 
by considering the presence of the interstitial 
shadow. Transbronchial lung biopsy (TBLB) was 
performed after BAL in 131 cases. We did not 
perform transbronchial lung cryobiopsy.
Diagnosis of BAL-induced AE-IPF 
(AE and non-AE groups)
The patients were diagnosed with AE-IPF 
if they met the following criteria established 
by Collard [12]: (1) previous or concurrent IPF 
diagnosis, (2) acute worsening or development 
of dyspnea (typically of 1-month duration), (3) 
computed tomography with new bilateral ground-
glass opacity and/or consolidation superimposed 
on a background pattern consistent with a UIP 
pattern that appeared as new shadows on the BAL 
site and the opposite lung field, and (4) deteriora-
tion not fully explained by cardiac failure or fluid 
overload. BAL-induced AE-IPF was defined as AE-
IPF occurring within 30 days post-BAL procedure 
(AE group). The patients who did not develop 
AE within 30 days after the BAL procedure were 
included in the non-AE group. 
Statistical analysis
Clinical data are expressed as mean ± stan-
dard deviation. We compared the AE and non-
AE groups using the Mann-Whitney U test for 
continuous variables and Fisher’s exact test for 
categorical variables. Youden’s index and receiver 
operating characteristic curve analysis were used 
to identify parameters affecting AE within 30 days 
post-BAL (Figure 2). Univariate logistic regression 
analyses were used to identify factors affecting 
BAL-induced AE-IPF. All statistical analyses were 
performed using EZR (Saitama Medical Center, 
Jichi Medical University, Saitama, Japan) [13]. 
Statistical significance was defined as p < 0.05. 
Previous BAL-induced AE-IPF reports
We searched the literature to identify previ-
ous BAL-induced AE-IPF reports published from 
1977 to 2019. We used PubMed (https://www.ncbi.
nlm.nih.gov/pubmed) for English reports and 
J-STAGE (https://www.jstage.jst.go.jp) for English 
and Japanese reports.
Patient and public involvement
The patients were not involved in the design, 
recruitment, or conduction of the studies includ-
ed in this analysis.
Results
Table 1 shows the baseline characteristics of 
the 155 patients. According to HRCT, 68 patients 
exhibited the “UIP pattern,” 57 showed a “proba-
Table 1. Baseline characteristics 
n = 155
Age [years] 68.6 ± 7.0
Male, n [%] 110 (70%)
Smoker, n [%] 113 (72%)
HRCT diagnosis 
[UIP/probable UIP/indeterminate for UIP]
68/57/30
PaO2 [mm Hg] 80.5 ± 12.5
KL-6 [U/mL] 1353 ± 1200
CRP [mg/dL] 0.4 ± 1.0
%FVC [%] 75.6 ± 18.3
%DLCO [%] 66.9 ± 23.3
GAP stage [I/II/III] 87/54/14
Confidence level of IPF [confident/high 
confidence/low confidence/unclassifiable]
70/49/20/16
Data are expressed as mean ± standard deviation. HRCT — high-resolution 
computed tomography; UIP — usual interstitial pneumonia; KL-6 — Krebs von 
den Lungen-6; CRP — C-reactive protein; FVC — forced vital capacity; DLCO — 
diffusing capacity of the lungs for carbon monoxide; GAP stage — Gender-Age-
Physiology stage; IPF — idiopathic pulmonary fibrosis
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ble UIP pattern”, and 30 were considered “indeter-
minate for UIP” [7]. The GAP stage was relatively 
mild [9]. Specifically, 87 patients were classified 
as stage I, 54 as stage II, and 14 as stage III.
Thirty-one patients had > 25% of lympho-
cytes in BAL fluid, suggesting the presence of 
non-IPF diseases, such as CHP and NSIP. One of 
these patients was diagnosed with NSIP based on 
surgical lung biopsy. The other 30 subjects did not 
undergo surgical lung biopsy. Using the Ryerson 
method, the 155 patients were classified into four 
groups according to IPF confidence level (confi-
dent, 70; high confidence, 49; low confidence, 20; 
unclassifiable, 16; Table 1).
The median AE-free survival after bronchosco-
py was 1057 days (range: 3–2263 days). Among the 
155 patients, 19 (12%) developed AE, and 25 (16%) 
died within the study period. The causes of death 
were AE (n = 6); respiratory failure (n = 15); and 
other causes (n = 4), including colon cancer (n = 
1), ovarian cancer (n = 1), liver failure due to viral 
hepatitis (n = 1), and heart failure (n = 1). The over-
all AE frequency throughout the whole observation 
period was 0.36% per 30 days and 4.4% per year.
Table 2 shows the clinical data of the five 
BAL-induced AE-IPF patients and non-AE pa-
tients. All five AE-IPF subjects were male, were 
past smokers, exhibited a UIP pattern on HRCT, 
and had confident IPF. Although partial pressure 
of oxygen (PaO2) (p = 0.062) and %FVC (p = 0.36) 
were not significantly different between the two 
groups, %DLCO was significantly lower in the AE 
group than in the non-AE group (p = 0.0074). Ad-
ditionally, the GAP stage was significantly more 
severe in the AE group than in the non-AE group 
(p = 0.0086). Further, the BAL recovery rate was 
significantly lower in the AE group than in the 
non-AE group (p = 0.029). There was no signifi-
cant difference in the lymphocyte fraction in BAL 
fluid between the two groups (p = 0.086), but the 
neutrophil fraction was significantly higher in the 
AE group than in the non-AE group (p = 0.0059).
Univariate logistic regression analysis results 
revealed that PaO2 < 75 mm Hg (p = 0.036), 
neutrophils in BAL ≥ 7% (p = 0.0061), %DLCO < 
50% (p = 0.019), GAP stage III (p = 0.034), and 
BAL recovery rates < 30% (p < 0.001) were the 
significant risk factors for post-BAL AE (Table 3). 
Figure 2. Receiver operating characteristic curve analysis was performed to obtain the parameters affecting acute exacerbation within 30 days 
of BAL. Sp — specificity; Se — sensitivity; PaO2 — partial pressure of oxygen; DLCO — diffusing capacity for carbon monoxide; BAL — broncho-
alveolar lavage
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Table 2. Clinical parameters of the AE group and non-AE group
AE [n = 5] non-AE [n = 150] P value
Age [years] 70.0 ± 5.2 68.6 ± 7.1 0.78
HRCT diagnosis (UIP/probable UIP/indeterminate for UIP) 5/0/0 63/56/30 0.14
Confidence level of IPF (confident/high confidence/low confidence/unclassifiable) 5/0/0/0 65/49/20/16 0.14
PaO2 [mm Hg] 68.6 ± 15.1 80.9 ± 12.2 0.062
KL-6 [U/mL] 1068 ± 258 1363 ± 1219 0.75
CRP [mg/dL] 1.8 ± 3.7 0.4 ± 0.8 0.10
%FVC [%] 70.4 ± 24.2 75.8 ± 17.7 0.36
%DLCO [%] 39.6 ± 9.1 67.9 ± 23.1 0.0074
GAP stage [I/II/III] 0/3/2 87/51/12 0.0086
TCC in BAL [105/mm3] 1.8 ± 1.0 2.4 ± 2.0 0.62
Neutrophils in BAL [%] 13.1 ± 10.5 4.3 ± 8.6 0.0059
Lymphocytes in BAL [%] 8.3 ± 8.9 18.5 ± 17.3 0.086
Recovery rates in BAL [%] 35.2 ± 17.6 52.0 ± 13.4 0.029
TBLB, n [%] 4 [80%] 127 [85%] 0.57
Data are expressed as mean ± standard deviation. AE — acute exacerbation; HRCT — high-resolution computed tomography; UIP — usual interstitial pneumonia; 
IPF — idiopathic pulmonary fibrosis; KL-6 — Krebs von den Lungen-6; CRP — C-reactive protein; FVC — forced vital capacity; DLCO — diffusing capacity of the lungs 
for carbon monoxide; GAP stage — Gender-Age-Physiology stage; TCC — total cell counts; BAL — bronchoalveolar lavage; TBLB — transbronchial lung biopsy
Table 3. Univariate logistic regression analysis of risk of acute exacerbation within 30 days post-bronchoalveolar lavage
HR 95% CI P value
Age [years] ≥ 65 1.41 0.15–13.0 0.76
> 65 Ref
PaO2 [mm Hg] ≥ 75 0.094 0.01–0.86 0.036
< 75 Ref
KL-6 [U/mL] ≥ 800 2.21 0.24–20.3 0.48
> 800 Ref
CRP [mg/dL] ≥ 0.3 1.42 0.22–8.78 0.70
< 0.3 Ref
%FVC [%] ≥ 60 0.40 0.06–2.55 0.33
< 60 Ref
%DLCO [%] ≥ 50 0.069 0.007–0.64 0.019
< 50 Ref
GAP stage III 7.67 1.17–50.4 0.034
I/II Ref
TCC [105/mm3] ≥ 2.0 0.22 0.025–2.10 0.19
< 2.0 Ref
Neutrophils in BAL [%] ≥ 7 22.9 2.43–215 0.0061
< 7 Ref
Lymphocytes in BAL [%] ≥ 6 0.070 0.007–0.65 0.019
< 6 Ref
Recovery rates in BAL [%] ≥ 30 0.037 0.005–0.25 < 0.001
< 30 Ref
HR — hazard ratio; CI — confidence interval; Ref — reference; KL-6 — Krebs von den Lungen-6; CRP — C-reactive protein; FVC — forced vital capacity; DLCO — dif-
fusing capacity of the lungs for carbon monoxide; AE — acute exacerbation; GAP stage — Gender-Age-Physiology stage; BAL — bronchoalveolar lavage
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Multivariate analysis was difficult to perform 
because the number of events was as small as five.
From the PubMed and J-STAGE databases, we 
discovered 12 cases from five reports that eval-
uated BAL-induced AE-IPF (Table 4) [8, 14–17]. 
All five of our cases improved and survived with 
systemic steroid therapy. Although the BAL recov-
ery rates were sometimes inadequate, the average 
BAL recovery rate of the previous and present 
studies was 48% (range: 17–80%). Additionally, 
the average predicted %FVC was 69.5% (range: 
42.5–99%), but the average %DLCO was 45% (range: 
16–81%). Furthermore, the C-reactive protein 
(CRP) level and/or neutrophil count in the BAL 
fluid were increased in a few cases.
Discussion and conclusions
In this study, we investigated the risk factors 
for BAL-induced AE-IPF. Our analyses revealed 
several risk factors for BAL-induced AE-IPF: (1) 
neutrophils in BAL ≥ 7%, which is an indicator of 
inflammation and instability in the lung, (2) the 
BAL recovery rate, which has not been reported 
as a risk factor previously, and (3) disease severity 
(PaO2 < 75 mm Hg, %DLCO < 50%, or GAP stage 
III). We first revealed that the BAL procedure itself 
was involved in the development of AE after the 
procedure.
Atkins et al. [18] reported that the incidence 
of AE was 4.1 per 100 patient-years based on a me-
ta-analysis from six clinical trials. Additionally, 
in the INPULSIS trial, a phase III randomized 
trial of nintedanib (n = 1066), Richeldi et al. [19] 
reported that AE-IPF occurred within 1 year in 
7.6% of patients who received a placebo. Among 
the 155 patients in our study, the incidence of 
AE within the first 30 days after the BAL proce-
dure was significantly higher than that over the 
entire observation period (first 30 days: 3.2 per 
100 patients-30 days; entire observation period: 
0.36 per 100 patients-30 days, p < 0.001), suggest-
ing a risk of AE in patients with IPF for at least 
30 days after BAL.
The high neutrophil level in BAL (≥ 7%) 
was a significant risk factor for AE after BAL 
(HR, 17.6; 95% CI, 1.17–265; p = 0.038; Table 3). 
The subjects with elevated neutrophil counts, 
as indicated by BAL, were predicted to have 
had increased lung activity at the time BAL was 
performed. This informed our conclusion that 
AE was likely to occur in these patients. Kinder 
et al. [20] reported increased neutrophils in BAL 
fluid to be an independent predictor of early 
mortality among patients with IPF. Sakamoto et 
al. [8] focused on the disease’s “instability”, an 
elevated CRP level (> 1 mg/dL) and/or increased 
white blood cell count (> 9000/mm3), which is 
unusual for stable IPF cases, were observed in six 
cases. Careful follow-up is important in patients 
with “instability,” but a high neutrophil level in 
BAL is a factor unknown before a BAL procedure 
and thus is not suitable for predicting the onset 
of BAL-induced AE.
We showed that a low BAL fluid recovery 
rate was a significant risk factor for AE after BAL 
(HR, 0.89; 95% CI, 0.81–0.97; p = 0.012; Table 
3). Ogata et al. [21] reported that the frequency of 
complications (mainly hypoxemia and fever, not 
only AE) after BAL increased if the BAL recovery 
rate was poor. Although the study conducted by 
Ogata et al. [21] included various diffuse lung 
diseases [i.e., interstitial lung disease (20.7%) 
and pathologies, including IPF (no description), 
sarcoidosis (23.9%), infection (11.6%), collagen 
vascular disease-associated interstitial pneumo-
nia (9.8%), and drug-induced interstitial pneu-
monia (9.8%)], our findings were consistent with 
those of their report. Poor BAL fluid recovery 
implies that much of the saline used for lavage 
remained in the lungs after the procedure. Saline 
is thought to be naturally absorbed into the blood 
vessels in the alveoli. If excessive saline remains 
in the alveoli, infection is promoted, and it is 
possible that AE occurs due to lung infection. 
Some reports have stated that saline lavage per 
se may cause lung injury. In an animal model, 
repeated BAL with saline resulted in acute lung 
injury [22, 23]. Matute-Bello et al. [23] reported 
that repeated lavage with saline reduced the 
surfactant lipid concentration in alveolar lining 
fluids and ultimately altered alveolar surface 
tension. Decreasing the surfactant causes lung 
injury by facilitating alveolar collapse, increasing 
mechanical injury, and impairing alveolar host 
defenses, a likely finding on both animal models 
and actual patients with IPF.
We found that disease severity (PaO2 < 
75 mm Hg, %DLCO < 50%, or GAP stage III) was 
a significant risk factor for AE after BAL only in 
the univariate analysis. Several risk factors for the 
development of AE, including low %FVC [24–28], 
low DLCO [24–26], and poor baseline oxygenation 
[24], have been previously identified. In a review 
of 12 case reports, Sakamoto et al. [8] reported 
that the severity of IPF before the BAL procedure 
was moderate to severe in patients who met any 
of the following criteria: (1) %FVC < 65%, (2) 
desaturation with exertion, and (3) DLCO ≤ 50%. 
The findings support our results and indicate that 
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some patients are already susceptible to AEs at 
the time of BAL. 
We conducted a literature review, but there 
were no reports of BAL-induced AE since Saka-
moto’s analysis in 2012 [8]. One reason might 
be publication bias. Since BAL-induced AE is 
a major significant complication, it is necessary 
to reduce the publication bias to evaluate the risk. 
Our study revealed that the first performance of 
BAL might cause AE. By contrast, Sakamoto et al. 
[8] reported that the first BAL did not induce AE 
in any of four cases with AE that had undergone 
at least one previous BAL.
According to Sakamoto et al. [8] only one case 
survived the AE. In the current study, all five cases 
were successfully discharged. The death of 10 of 
the 12 patients reported in the literature (Table 4.) 
underscores the necessity of addressing AEs due 
to BAL. The therapies that we administered to the 
five patients with AEs in our study were similar 
to those administered to the subjects in the study 
conducted by Sakamoto et al. [8]. These therapies 
are outlined in Table 4. Additionally, advances in 
oxygen therapy and medical treatment may have 
contributed to improved mortality in our cases. Vi-
anello et al. [29] evaluated the utility of a high-
flow nasal cannula for patients with AE-IPF who 
did not respond to treatment using a conventional 
nasal cannula. In our cases, a high-flow nasal 
cannula was used in two cases. It is not possible 
to confirm whether the cases we reviewed used 
a high-flow nasal cannula.
This study’s AE incidence (5 in 155 cases, 
3.2%) is higher than in previous reports (4 in 
202 cases, 1.9% [8]; none of 57 cases, 0% [21]; and 
two in 104 cases, 1.9% [15]). Although no detailed 
patient background was reported by Sakamoto et 
al. [8], the average age was 64 years, which was 
younger than that in our study (68.6 years). In 
addition, a surgical lung biopsy was performed 
in 47.3% of cases, suggesting that there are many 
relatively mild cases in which surgical lung biop-
sy is possible. Regarding Ogata’s report [21], there 
is no patient background limited to idiopathic 
interstitial pneumonias, but the overall average 
age is as young as 58.7 years. These findings are in 
line with our findings that high severity is a risk 
factor for AEs. In Suga’s report [15], the overall 
patient background is not mentioned.
Our study had some limitations. First, this 
was a single-center retrospective study with 
a small number of cases. Only five patients 
developed AE after BAL. Since the sample size 
was small, further studies with more patients are 
required. Second, the effects of the type of fiber 
used in bronchoscopy, years of experience of the 
examiner, examination time, and other broncho-
scopic procedures on the development of AEs 
were not analyzed in the current study. Finally, 
BAL may not have been the cause of AE in some 
cases. An increase in the neutrophil level in BAL 
(≥ 7%) was confirmed in four cases. These results 
suggest that latent infection or disease progres-
sion may have existed before BAL.
Clinical implications/future directions
In conclusion, patients with suspected IPF 
may develop AE after BAL and should be moni-
tored carefully. Disease severity, high neutrophil 
levels in BAL, and poor BAL recovery rates may 
be risk factors for BAL-induced AEs and need to 
be confirmed in a larger, multi-center prospective 
study. We will be able to assess some adminis-
tration parameters, such as the number of years 
of experience of the examiner and examination 
times. Other factors to consider are the lavage 
equipment and its components.
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